Cengild Medical which is headed for the ACE Market aiming to raise RM72 million, could not be much more excited as its IPO shares was been oversubscribed by more than 44 times.
The IPO involves the issuance of 218,800,000 IPO Shares comprising, the institutional offering of 162,860,000 IPO Shares to institutional and selected investors, at the institutional price; and the retail offering of 55,940,000 IPO Shares to the Malaysian public.
Tricor Investor & Issuing House Services Sdn Bhd has announced the completion of the book-building process under the Institutional Offering with price fixed at RM0.33 per IPO Share.
As the final retail price equals the retail price of RM0.33 per IPO Share, it added that there will be no refund to be made to the successful applicants under the Retail Offering. A total of 17,462 applications for 1,863,985,200 IPO Shares with a value of RM615,115,116.00 were received from the Malaysian public for the 40,940,000 IPO Shares made available for application by the Malaysian public, which represents an overall oversubscription rate of 44.53 times. For the Bumiputera public portion, a total of 8,075 applications for 592,643,800 IPO Shares were received which represents an oversubscription rate of 27.95 times.
For the remaining Malaysian public portion, a total of 9,387 applications for 1,271,341,400 IPO Shares were received which represents an oversubscription rate of 61.11 times.
The 15,000,000 IPO shares made available for application by the eligible directors, eligible key senior management, eligible employees, and persons who have contributed to the success of Cengild Medical and its subsidiaries were fully
subscribed. For the Institutional Offering, the Sole Bookrunner has confirmed that the 162,860,000 IPO Shares offered to institutional and selected investors have also been fully subscribed. The notices of allotment will be despatched to all successful applicants on or before 15 April 2022.
Hong Leong Investment Bank Berhad is the Principal Adviser, Sponsor, Sole Underwriter and Sole Bookrunner for the IPO
